Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive HCL. This open-label, phase 2 study enrolled patients with BRAF V600E mutation-positive HCL...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 2, 2023
|
| In: |
Blood
Year: 2023, Volume: 141, Issue: 9, Pages: 996-1006 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2021013658 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2021013658
|
| Author Notes: | Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, and Vivek Subbiah |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1847646522 | ||
| 003 | DE-627 | ||
| 005 | 20240328080448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2021013658 |2 doi | |
| 035 | |a (DE-627)1847646522 | ||
| 035 | |a (DE-599)KXP1847646522 | ||
| 035 | |a (OCoLC)1389529837 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kreitman, Robert |e VerfasserIn |0 (DE-588)1198155914 |0 (DE-627)1680064851 |4 aut | |
| 245 | 1 | 0 | |a Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia |c Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, and Vivek Subbiah |
| 264 | 1 | |c March 2, 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.06.2023 | ||
| 520 | |a BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive HCL. This open-label, phase 2 study enrolled patients with BRAF V600E mutation-positive HCL refractory to first-line treatment with a purine analog or relapsed after ≥2 prior lines of treatment. Patients received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed objective response rate (ORR) per criteria adapted from National Comprehensive Cancer Network-Consensus Resolution guidelines. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Fifty-five patients with BRAF V600E mutation-positive HCL were enrolled. The investigator-assessed ORR was 89.0% (95% confidence interval, 77.8%-95.9%); 65.5% of patients had a complete response (without minimal residual disease [MRD]: 9.1% [negative immunohistochemistry of bone marrow {BM} biopsy], 12.7% [negative BM aspirate flow cytometry {FC}], 16.4% [negative immunohistochemistry and/or FC results]; with MRD, 49.1%), and 23.6% had a partial response. The 24-month DOR was 97.7% with 24-month PFS and OS rates of 94.4% and 94.5%, respectively. The most common treatment-related adverse events were pyrexia (58.2%), chills (47.3%), and hyperglycemia (40.0%). Dabrafenib plus trametinib demonstrated durable responses with a manageable safety profile consistent with previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at www.clinicaltrials.gov as #NCT02034110. | ||
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ravandi, Farhad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hutchings, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gazzah, Anas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michallet, Anne-Sophie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wainberg, Zev A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stein, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 700 | 1 | |a de Jonge, Maja J. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Willenbacher, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Grève, Jacques |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arons, Evgeny |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ilankumaran, Palanichamy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burgess, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gasal, Eduard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 141(2023), 9 vom: März, Seite 996-1006 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:9 |g month:03 |g pages:996-1006 |g extent:11 |a Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2021013658 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230607 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |d 50000 |e 910000PD136406300 |e 910100PD136406300 |e 50000PD136406300 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1847646522 |e 433003302X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 07.06.2023"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"March 2, 2023"}],"title":[{"title":"Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia","title_sort":"Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"family":"Kreitman","display":"Kreitman, Robert","given":"Robert","role":"aut"},{"role":"aut","given":"Philippe","family":"Moreau","display":"Moreau, Philippe"},{"display":"Ravandi, Farhad","family":"Ravandi","role":"aut","given":"Farhad"},{"role":"aut","given":"Martin","display":"Hutchings, Martin","family":"Hutchings"},{"given":"Anas","role":"aut","family":"Gazzah","display":"Gazzah, Anas"},{"family":"Michallet","display":"Michallet, Anne-Sophie","role":"aut","given":"Anne-Sophie"},{"given":"Zev A.","role":"aut","display":"Wainberg, Zev A.","family":"Wainberg"},{"given":"Alexander","role":"aut","display":"Stein, Alexander","family":"Stein"},{"role":"aut","given":"Sascha","display":"Dietrich, Sascha","family":"Dietrich"},{"family":"de Jonge","display":"de Jonge, Maja J. A.","role":"aut","given":"Maja J. A."},{"family":"Willenbacher","display":"Willenbacher, Wolfgang","role":"aut","given":"Wolfgang"},{"family":"De Grève","display":"De Grève, Jacques","given":"Jacques","role":"aut"},{"role":"aut","given":"Evgeny","display":"Arons, Evgeny","family":"Arons"},{"given":"Palanichamy","role":"aut","family":"Ilankumaran","display":"Ilankumaran, Palanichamy"},{"role":"aut","given":"Paul","display":"Burgess, Paul","family":"Burgess"},{"role":"aut","given":"Eduard","family":"Gasal","display":"Gasal, Eduard"},{"display":"Subbiah, Vivek","family":"Subbiah","given":"Vivek","role":"aut"}],"relHost":[{"id":{"issn":["1528-0020"],"eki":["266886647"],"zdb":["1468538-3"]},"recId":"266886647","pubHistory":["1.1946 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"part":{"year":"2023","pages":"996-1006","text":"141(2023), 9 vom: März, Seite 996-1006","extent":"11","volume":"141","issue":"9"},"note":["Gesehen am 21.04.2023"],"titleAlt":[{"title":"Blood online"}],"origin":[{"publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedKey":"1946"}],"title":[{"title":"Blood","title_sort":"Blood","subtitle":"journal of the American Society of Hematology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemiaBlood","corporate":[{"role":"isb","display":"American Society of Hematology"}]}],"id":{"doi":["10.1182/blood.2021013658"],"eki":["1847646522"]},"name":{"displayForm":["Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, and Vivek Subbiah"]},"physDesc":[{"extent":"11 S."}],"recId":"1847646522"} | ||
| SRT | |a KREITMANRODABRAFENIB2202 | ||